🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against superbug strains of the pathogen, according to health experts.

An International Health Concern

Cases of gonorrhoea are on the rise around the world, with estimates suggesting in excess of 82 million new cases per year. Especially elevated rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone signifies a significant shift in the management of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Results and Worldwide Availability

According to data published in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The study included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in many developing nations.

Doctors directly involved have voiced optimism. Having a one-pill regimen of this kind is seen as a "game-changer" for public health efforts. This is considered crucial to alleviate the strain of the infection for people and to halt the transmission of untreatable gonorrhoea worldwide.